CA3070115A1 - Inhibitors of rho associated coiled-coil containing protein kinase - Google Patents
Inhibitors of rho associated coiled-coil containing protein kinase Download PDFInfo
- Publication number
- CA3070115A1 CA3070115A1 CA3070115A CA3070115A CA3070115A1 CA 3070115 A1 CA3070115 A1 CA 3070115A1 CA 3070115 A CA3070115 A CA 3070115A CA 3070115 A CA3070115 A CA 3070115A CA 3070115 A1 CA3070115 A1 CA 3070115A1
- Authority
- CA
- Canada
- Prior art keywords
- lower alkyl
- alkyl
- group
- cycloalkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535611P | 2017-07-21 | 2017-07-21 | |
| US62/535,611 | 2017-07-21 | ||
| PCT/US2018/043335 WO2019018855A1 (en) | 2017-07-21 | 2018-07-23 | ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3070115A1 true CA3070115A1 (en) | 2019-01-24 |
Family
ID=65015613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3070115A Pending CA3070115A1 (en) | 2017-07-21 | 2018-07-23 | Inhibitors of rho associated coiled-coil containing protein kinase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11479533B2 (https=) |
| EP (1) | EP3654970A4 (https=) |
| JP (3) | JP7383598B2 (https=) |
| CN (1) | CN111050766A (https=) |
| CA (1) | CA3070115A1 (https=) |
| EA (1) | EA202090306A1 (https=) |
| WO (1) | WO2019018855A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019161162A1 (en) * | 2018-02-16 | 2019-08-22 | Constellation Pharmaceuticals, Inc. | P300/cbp hat inhibitors |
| JP7531379B2 (ja) * | 2019-12-31 | 2024-08-09 | 財團法人工業技術研究院 | βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用 |
| CN111707830B (zh) * | 2020-07-16 | 2023-08-15 | 首都医科大学附属北京朝阳医院 | Rock激酶活性在辅助诊断肺损害中的应用 |
| CN111707832B (zh) * | 2020-07-16 | 2023-08-15 | 首都医科大学附属北京朝阳医院 | Rock激酶活性在辅助诊断肾损害中的应用 |
| US20240423998A1 (en) * | 2021-11-29 | 2024-12-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| JPWO2024075838A1 (https=) * | 2022-10-07 | 2024-04-11 | ||
| WO2025017500A1 (en) * | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations of rock2 inhibitors for cns disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053941A2 (en) | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| JP2011507850A (ja) | 2007-12-21 | 2011-03-10 | ザ スクリプス リサーチ インスティチュート | Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ |
| CN105102448B (zh) * | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
| EP3019475A1 (en) | 2013-07-08 | 2016-05-18 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| WO2015070170A1 (en) * | 2013-11-08 | 2015-05-14 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| JP2017523214A (ja) | 2014-08-05 | 2017-08-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環キナーゼ阻害剤 |
| US11926596B2 (en) * | 2017-07-21 | 2024-03-12 | Kadmon Corporation, Llc | Inhibitors of Rho associated coiled-coil containing protein kinase |
| EP3675861A4 (en) * | 2017-09-01 | 2021-01-06 | Kadmon Corporation, LLC | ALPHA SUPERWINDING PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO |
-
2018
- 2018-07-23 WO PCT/US2018/043335 patent/WO2019018855A1/en not_active Ceased
- 2018-07-23 EP EP18834641.5A patent/EP3654970A4/en active Pending
- 2018-07-23 JP JP2020502709A patent/JP7383598B2/ja active Active
- 2018-07-23 EA EA202090306A patent/EA202090306A1/ru unknown
- 2018-07-23 CN CN201880049759.5A patent/CN111050766A/zh active Pending
- 2018-07-23 US US16/632,662 patent/US11479533B2/en active Active
- 2018-07-23 CA CA3070115A patent/CA3070115A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101681A patent/JP7778745B2/ja active Active
-
2025
- 2025-10-15 JP JP2025173688A patent/JP2026020169A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111050766A (zh) | 2020-04-21 |
| WO2019018855A1 (en) | 2019-01-24 |
| EA202090306A1 (ru) | 2020-06-25 |
| JP7383598B2 (ja) | 2023-11-20 |
| US11479533B2 (en) | 2022-10-25 |
| JP2023126245A (ja) | 2023-09-07 |
| JP2020527585A (ja) | 2020-09-10 |
| JP7778745B2 (ja) | 2025-12-02 |
| EP3654970A4 (en) | 2021-03-17 |
| JP2026020169A (ja) | 2026-02-06 |
| EP3654970A1 (en) | 2020-05-27 |
| US20200165206A1 (en) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230174519A1 (en) | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | |
| US11479533B2 (en) | Inhibitors of Rho associated coiled-coil containing protein kinase | |
| US10125144B2 (en) | Rho kinase inhibitors | |
| CA2926478C (en) | Rho kinase inhibitors | |
| CN106536480B (zh) | 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| KR20160118368A (ko) | 보체 매개된 장애의 치료를 위한 에터 화합물 | |
| WO2015157556A1 (en) | Treatment of gvhd | |
| JP7089596B2 (ja) | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 | |
| US20240190827A1 (en) | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | |
| CA3073931C (en) | Inhibitors of rho associated coiled-coil containing protein kinase | |
| EA046894B1 (ru) | Ингибиторы rho-ассоциированной, содержащей суперспираль протеинкиназы | |
| HK40085319A (en) | Rho kinase inhibitors | |
| EA043363B1 (ru) | Ингибиторы rho-ассоциированной суперспираль содержащей протеинкиназы | |
| HK1214813B (zh) | Rho激酶抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220901 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240718 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250521 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250521 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250630 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250630 |